- Home
- SGC vs RIGL Comparison
SGC vs RIGL Comparison
Compare SGC & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGC
- RIGL
- Stock Information
- Founded
- SGC 1920
- RIGL 1996
- Country
- SGC United States
- RIGL United States
- Employees
- SGC N/A
- RIGL N/A
- Industry
- SGC Apparel
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- SGC Consumer Discretionary
- RIGL Health Care
- Exchange
- SGC Nasdaq
- RIGL Nasdaq
- Market Cap
- SGC 155.7M
- RIGL 335.5M
- IPO Year
- SGC N/A
- RIGL 2000
- Fundamental
- Price
- SGC $10.30
- RIGL $18.62
- Analyst Decision
- SGC Strong Buy
- RIGL Buy
- Analyst Count
- SGC 3
- RIGL 5
- Target Price
- SGC $17.00
- RIGL $36.40
- AVG Volume (30 Days)
- SGC 55.0K
- RIGL 192.9K
- Earning Date
- SGC 08-05-2025
- RIGL 08-05-2025
- Dividend Yield
- SGC 5.41%
- RIGL N/A
- EPS Growth
- SGC N/A
- RIGL N/A
- EPS
- SGC 0.45
- RIGL 2.08
- Revenue
- SGC $563,931,000.00
- RIGL $203,077,000.00
- Revenue This Year
- SGC N/A
- RIGL $14.41
- Revenue Next Year
- SGC $4.31
- RIGL $15.97
- P/E Ratio
- SGC $23.04
- RIGL $9.02
- Revenue Growth
- SGC 2.28
- RIGL 70.16
- 52 Week Low
- SGC $9.11
- RIGL $7.48
- 52 Week High
- SGC $20.75
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- SGC 52.34
- RIGL 39.75
- Support Level
- SGC $9.99
- RIGL $18.14
- Resistance Level
- SGC $10.22
- RIGL $19.21
- Average True Range (ATR)
- SGC 0.32
- RIGL 0.84
- MACD
- SGC 0.02
- RIGL -0.28
- Stochastic Oscillator
- SGC 55.36
- RIGL 10.89
About SGC Superior Group of Companies Inc.
Superior Group Of Companies Inc designs apparel products. The company's operating segment includes Branded Products; Healthcare Apparel and Contact Centers. It generates maximum revenue from the Branded Products segment. The Branded Products segment produce and sell customized merchandising solutions, promotional products and branded uniform programs to customers.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.